Erschienen in:
01.02.2016 | Gastrointestinal Oncology
S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer
verfasst von:
Manabu Yamamoto, MD, PhD, FACS, Yoshihisa Sakaguchi, MD, PhD, FACS, Nao Kinjo, MD, PhD, Shohei Yamaguchi, MD, PhD, Akinori Egashira, MD, PhD, Kazuhito Minami, MD, PhD, Yasuharu Ikeda, MD, PhD, Masaru Morita, MD, PhD, FACS, Yasushi Toh, MD, PhD, FACS, Takeshi Okamura, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 2/2016
Einloggen, um Zugang zu erhalten
Abstract
Background
S-1 adjuvant chemotherapy is commonly administered postoperatively for stage II and III advanced gastric cancer.
Methods
This study included 113 patients treated with S-1 adjuvant chemotherapy after surgery for stage II and III advanced gastric cancer. These patients were divided into 4 groups: group A (n = 63), who had a longer duration (≥6 months) and earlier S-1 administration (≤6 weeks) after surgery; group B (n = 16), who had a longer and later S-1 administration (>6 weeks) after surgery; group C (n = 27), who had a shorter duration (<6 months) and earlier S-1 administration after surgery; and group D (n = 7), who had a shorter and later S-1 administration after surgery.
Results
The recurrence rates in groups A, B, C, and D were 15.7, 43.8, 44.4, and 57.1 %, respectively (A vs. B, p < 0.05, A vs. C and D, p < 0.01). The survival time of group A was significantly longer than that of other groups (p < 0.005). In addition, the survival time of patients with severe complications was significantly shorter than that of patients with non-severe complications (p < 0.05). An earlier S-1 administration after surgery was the only independent prognostic factor in the multivariate analysis.
Conclusions
The prognosis of advanced gastric cancer was significantly related to the start of S-1 adjuvant treatment within 6 weeks after surgery.